SCHEMBL217571

SCHEMBL217571

O=C(CO)OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.77
MAPK1 P28482 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
TDP1 Q9NUW8 3/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A3 Q01959 1/20 0.59
KMT2A Q03164 1/20 0.59
LMNA P02545 3/20 0.53
HCAR2 Q8TDS4 1/20 0.53
PAM P19021 1/20 0.52
CDC25B P30305 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL23001581 0.98 ALDH1A1 (0.74) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Hydrochloric Acid SCHEMBL29901825 0.98 ALDH1A1 (0.74) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Acetic Acid SCHEMBL31078051 0.94 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Cyclopropane SCHEMBL29003079 0.94 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Alcohol SCHEMBL21245486 0.94 ALDH1A1 (0.69) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Propionic Acid SCHEMBL31077917 0.91 ALDH1A1 (0.65) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
SCHEMBL361779 0.87 ALDH1A1 (1.00) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
SCHEMBL6784181 0.85 ALDH1A1 (0.96) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
Trifluoromethanesulfonic Acid SCHEMBL5035423 0.85 ALDH1A1 (0.57) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2
SCHEMBL294341 0.84 ALDH1A1 (0.73) ALDH1A1MAPK1L3MBTL1TDP1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1033 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503489-B2 Method for producing antibody-drug conjugate DAIICHI SANKYO COMPANY, LIMITED (JP) 2025-12-23 US claimed
EP-3677589-B1 IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO CO LTD (JP) 2025-11-26 EP claimed
WO-2025125052-A1 METHOD FOR ACTIVATING A HETEROGENEOUS CATALYST IN THE PRESENCE OF A MULTIFUNCTIONAL ACID COMPOUND IFP Energies Nouvelles (FR) 2025-06-19 WO claimed
CN-119855060-B PCB (printed circuit board) ink-jet printing pretreatment agent, preparation method thereof and PCB ink-jet printing method 深圳市板明科技股份有限公司 2025-06-17 CN claimed
CN-119855060-A PCB (printed circuit board) ink-jet printing pretreatment agent, preparation method thereof and PCB ink-jet printing method 深圳市板明科技股份有限公司 2025-04-18 CN claimed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 US claimed
CN-119350290-A Method for preparing 1, 4-dioxane-2-ketone from ethylene carbonate 青岛科技大学 2025-01-24 CN claimed
CN-119350291-A Six-membered oxygen heterocyclic lactone, degradable polyether ester and preparation and degradation methods thereof 青岛科技大学 2025-01-24 CN claimed
CN-117185976-B Synthesis method of compound L635 深圳市灵兰生物医药科技有限公司 2024-12-31 CN claimed
US-20240376147-A1 METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-11-14 US claimed
US-6140317-A AS INHIBITORS OF PROTEIN KINASES AND HAVE ANTITUMOUR ACTIVITY NOVARTIS AG (CH) 2000-10-31 US claimed
EP-0888349-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-01-07 EP claimed
WO-1998043973-A1 INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION OF PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 1998-10-08 WO claimed
EP-0836605-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF Novartis AG (CH) 1998-04-22 EP claimed
WO-1997027199-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1997-07-31 WO claimed
WO-1997002266-A1 PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF NOVARTIS AG (CH) 1997-01-23 WO claimed
US-5466701-A Degenerative diseases STERLING WINTHROP INC. (US) 1995-11-14 US claimed
US-5378720-A Treatment of rheumatoid arthritis, emphysema, pancreatitis STERLING WINTHROP INC. (US) 1995-01-03 US claimed
US-5336692-A High-molecular-weight petrolatum, solvent and a compound both hydrophobic and hydrophilic; protective coatings for skin; moisturizers; spreadability; long-lasting MEDICIS PHARMACEUTICAL CORPORATION (US) 1994-08-09 US claimed
WO-1992000077-A1 IMPROVED OINTMENT BASE AND METHOD OF USE MEDICIS CORPORATION (US) 1992-01-09 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503489-B2 Method for producing antibody-drug conjugate UGT1A9, ALB, MRPL21 ALDH1A1 257/4885MAPK1 2254/4885L3MBTL1 4302/4885
US-20240376147-A1 METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE UGT1A9, ALB, MRPL21 ALDH1A1 257/4885MAPK1 2254/4885L3MBTL1 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.